7qt2
From Proteopedia
(Difference between revisions)
Line 8: | Line 8: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7qt2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7qt2 OCA], [https://pdbe.org/7qt2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7qt2 RCSB], [https://www.ebi.ac.uk/pdbsum/7qt2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7qt2 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7qt2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7qt2 OCA], [https://pdbe.org/7qt2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7qt2 RCSB], [https://www.ebi.ac.uk/pdbsum/7qt2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7qt2 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Poorly immunogenic small molecules pose challenges for the production of clinically efficacious vaccines and antibodies. To address this, we generate an immunization platform derived from the immunogenic surface coat of the African trypanosome. Through sortase-based conjugation of the target molecules to the variant surface glycoprotein (VSG) of the trypanosome surface coat, we develop VSG-immunogen array by sortase tagging (VAST). VAST elicits antigen-specific memory B cells and antibodies in a murine model after deploying the poorly immunogenic molecule fentanyl as a proof of concept. We also develop a single-cell RNA sequencing (RNA-seq)-based computational method that synergizes with VAST to specifically identify memory B cell-encoded antibodies. All computationally selected antibodies bind to fentanyl with picomolar affinity. Moreover, these antibodies protect mice from fentanyl effects after passive immunization, demonstrating the ability of these two coupled technologies to elicit therapeutic antibodies to challenging immunogens. | ||
+ | |||
+ | A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl.,Triller G, Vlachou EP, Hashemi H, van Straaten M, Zeelen JP, Kelemen Y, Baehr C, Marker CL, Ruf S, Svirina A, Chandra M, Urban K, Gkeka A, Kruse S, Baumann A, Miller AK, Bartel M, Pravetoni M, Stebbins CE, Papavasiliou FN, Verdi JP Cell Rep. 2023 Feb 28;42(2):112049. doi: 10.1016/j.celrep.2023.112049. Epub 2023 , Jan 30. PMID:36719797<ref>PMID:36719797</ref> | ||
+ | |||
+ | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
+ | </div> | ||
+ | <div class="pdbe-citations 7qt2" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> |
Current revision
Antibody FenAb208 - fentanyl complex
|